Schizophrenia and Related Disorders Clinical Trial
Official title:
Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia: A Prospective 3-month Pilot Study
It is well established in the scientific literature that people with schizophrenia smoke tobacco cigarettes at rates up to three times that of the general population, relapse more frequently, and die an average of 25 years earlier from cigarette smoking and other life-style attributable illnesses. Electronic cigarettes (e-cigarettes) are becoming increasingly popular with smokers worldwide and new research suggests that e-cigarettes are appealing to smokers with schizophrenia. There is a paucity of research focused on the experience of smokers with schizophrenia who decide to try an e-cigarette. A well-designed prospective-observational study is needed to learn more about the influence of e-cigarette use on cigarette smoking behavior and mental and physical health among smokers with schizophrenia. In response, the investigators have designed a study titled, Role of an electronic cigarette on smoking displacement in smokers with schizophrenia: A prospective 3-month pilot study (SchizEcig).
This is a prospective 3 month pilot study to observe cigarette use behavior among people with a schizophrenia spectrum disorder diagnosis who smoke conventional tobacco cigarettes, do not intend to reduce or quit smoking, and are invited to use an e-cigarette. The investigators are interested to know if e-cigarette use is associated with cigarette smoking displacement. Displacement is defined as switching from conventional tobacco cigarettes to e-cigarettes. The investigators will also monitor for physical and mental health, including blood pressure, weight, and scores from the Scale for the Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS) as well as any reported adverse events participants' feel are attributed to e-cigarette use and participants' perceptions of the sensory experience associated with e-cigarette use. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05083377 -
Clozapine Use Pattern in the Province of Seville
|
||
Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
Recruiting |
NCT06134661 -
Accelerated rTMS for Psychomotor Slowing
|
N/A | |
Completed |
NCT01433094 -
Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia
|
N/A | |
Terminated |
NCT05526833 -
An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study
|
N/A | |
Recruiting |
NCT05982158 -
Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices
|
N/A | |
Active, not recruiting |
NCT06175559 -
Embedded Narrative in Interactive Game Design for Improving Medication Adherence of Schizophrenia
|
N/A | |
Active, not recruiting |
NCT05673941 -
"InMotion" - Physical Training With Creative Movement as an Intervention for Adults With Schizophrenia
|
N/A | |
Recruiting |
NCT02916810 -
TMS for Symptom Reduction in Schizophrenia
|
N/A | |
Recruiting |
NCT05958875 -
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
|
Phase 4 | |
Recruiting |
NCT03525054 -
Semantic and Syntactic Computerized Analysis of Free Speech
|
||
Recruiting |
NCT05389345 -
tDCS and Executive Function Training for Schizophrenia
|
N/A | |
Completed |
NCT05601050 -
Linguistic Predictors of Outcomes in Psychosis
|
||
Completed |
NCT03921450 -
Overcoming Psychomotor Slowing in Psychosis (OCoPS-P)
|
N/A | |
Completed |
NCT06231407 -
Increasing Medication Check Participation Through Applying CT-r
|
N/A | |
Recruiting |
NCT04478838 -
"Extended" (Alternate Day) Antipsychotic Dosing
|
Phase 4 | |
Completed |
NCT04366401 -
Efficacy of Prebiotic and Probiotic Dietary Modulation in Schizophrenic Disorders
|
N/A | |
Completed |
NCT04612777 -
A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses
|
N/A | |
Not yet recruiting |
NCT06191965 -
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
|
Phase 2/Phase 3 | |
Recruiting |
NCT04321759 -
Comparative Effectiveness of CET vs. SST in SMI (Serious Mental Illness)
|
N/A |